2Seventy Bio Inc

2Seventy Bio — Investor Presentation (March 2023)

40 slides from 2Seventy Bio's investor presentation, Mar 7, 2023

  1. Slide 1: Unleash Time: 2seventy bio company presentation March 2023

    Unleash Time 2seventy bio company presentation March 2023

  2. Slide 2: Cautionary note regarding forward-looking statements

    Cautionary note regarding forward-looking statements These slides and the accompanying oral presentation may contain “forward-looking statements”. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development, man

  3. Slide 3: The sole mission of 2seventy is to unleash the curative potential of the T cell

    The sole mission of 2seventy is to “unleash the curative potential of the T cell” Our experience in drug development and deep execution capabilities in cell therapy allow us to design & deliver multi-layered, multi-modality T cell-based solutions that have the potential to address and overcome the i

  4. Slide 4: Purpose-built strategy to unleash the curative potential of the T cell

    Purpose-built strategy to unleash the curative potential of the T cell 4 • Unleash the T cell. We focus on autologous T cell therapies: proven modality with curative potential • Advanced engineering, broad scope. We apply cell engineering across both heme and solid tumors – bespoke therapies to opti

  5. Slide 5: 2seventy – At a Glance

    ABECMA Commercial ABECMA Development BMS 50/50 US $297M 2022 / $470-570M 2023* Potential $2-3B US Peak 3rd Line K3 & FDA Submission Initiation of Front Line K9 ABECMA Capacity Expansion Predictable Delivery ABECMA profitable in 2023** Cash runway into 2026** 410 employees 2seventy – At a Glance Unle

  6. Slide 6: 2022 – 2seventy's Foundational First Year

    2022 – 2seventy’s Foundational First Year Reset & rebalanced company size, shape & burn Company/Platform Built in-house DP capability to support product engine Launched “Unleash T cell” vision, culture & core values End of year runway into 2025 – now extended to 2026** ABECMA Pipeline • $297M U.S. t

  7. Slide 7: 2023 Goals and Long-Term Drivers

    • Total US revenue $470-570M shared with BMS** • Present and publish KarMMa-3 data • U.S. Approval in 3rd line • Initiate KarMMa-9 2023 Goals and Long-Term Drivers Longer-Term Drivers ABECMA Pipeline • Drive toward $2-3B ABECMA U.S. peak sales potential* • Path to profitability and sustainability •

  8. Slide 8: ABECMA potential to be $2-3B market opportunity in US

    ABECMA® potential to be $2-3B* market opportunity in US driven by label expansion, increased capacity and double-digit market growth 8 2022 Launch and Lead • Ongoing significant demand • Increased capacity across supply chain • RWE validates efficacy & safety even in difficult-to-treat populations •

  9. Slide 9: Real-world MM treatment decisions are practical and patient-driven

    Real-world MM treatment decisions are practical and patient-driven 9 Efficacy Potential for deep and durable response Safety Predictable and manageable side-effect profile Real World Experience Physician real-world experience with the product Availability Slot availability in the relevant time frame

  10. Slide 10: ABECMA Financial Outlook

    ABECMA Financial Outlook Strong US revenue growth. Blockbuster potential. 2024-25 cashflow significantly reduces future capital needs. 10 0 100 200 300 400 500 600 2Q-4Q21 1Q-3Q22 FY22 FY23 FY24 FY25 FY26-30 1st 3 quarters of launch $134M 2nd 3 quarters of launch $203M $94M in 4Q22; $297M for FY22*

  11. Slide 11: Addressable U.S. Patients on ABECMA label over time

    Addressable U.S. Patients on ABECMA label over time M u lt ip le M ye lo m a KarMMa-3 results and planned KarMMa-9 front-line study have the potential to drive label expansion into broad U.S. market opportunity Total Addressable U.S. Patient Population: ~21,000 0 5,000 10,000 15,000 20,000 25,000 20

  12. Slide 12: KarMMa-2 and KarMMa-3 data support ABECMA in front-line setting

    • RRMM after 2-4 prior lines of therapy and refractory to the last regimens); clinically meaningful and statistically significant improvement in PFS compared with standard regimens • Median PFS of 13.3 months vs. 4.4 months (HR:0.49) • Planned BLA submission early 2023 KarMMa-2 and KarMMa-3 data sup

  13. Slide 13: KarMMa-2 data supports potential of ABECMA in NDMM

    KarMMa-2 data supports potential of ABECMA in NDMM – suboptimal responders post transplant KarMMa-2 cohort 2c in <VGPR post transplant demonstrate promising efficacy in 31 patients • Patients without lenalidomide maintenance (n=24): ORR=87%, CRR=74%, PD=5/24, mDOR=29.8 months, mPFS: not reached • Pa

  14. Slide 14: KarMMa-3 Summary

    KarMMa-3 Summary 14 These results support the use of ide-cel in patients with earlier-line relapse and triple-class–exposed RRMM, a patient population with poor survival outcomes • KarMMa-3 is the first randomized phase 3 clinical study to directly compare a CAR T cell therapy with standard regimens

  15. Slide 15: KarMMa-3 study design

    KarMMa-3 study design (NCT03651128) 15 GC-LTFU-001 study Post-treatment follow-up period Primary endpoint ▪ PFS (by IRC) Key secondary endpoints ▪ ORR (by IRC), OS Other secondary endpoints ▪ CR rate,h DOR,h TTR,h MRD ▪ Safety Survival follow-upg PFS follow-upe; 3-month safety follow-upf Survival fo

  16. Slide 16: Baseline characteristics were generally balanced between treatment arms

    Baseline characteristics were generally balanced between treatment arms KarMMa-3 Baseline demographics and characteristics 16 Characteristic Ide-cel (n = 254) Standard regimens (n = 132) Median (range) age, years 63 (30–81) 63 (42–83) Sex, male, n (%) 156 (61) 79 (60) Median (range) time from diagno

  17. Slide 17: Ide-cel resulted in significantly longer PFS than standard regimens

    Treatment with ide-cel resulted in a significantly longer PFS than standard regimens, with a 51% lower risk of disease progression or death (Hazard Ratio: 0.49) Standard regimens 100 80 60 40 20 0 0 P ro g re ss io n -f re e su rv iv al , % Months since randomization 254 132 3 6 9 12 15 18 21 24 27

  18. Slide 18: KarMMa-3 safety: CRS and neurotoxicity

    Ide-cel (n = 225) CRS,a n (%) Any grade 197 (88) Grade 3/4 9 (4) Grade 5 2 (1) Median (range) time to first onset, daysb 1.0 (1.0–14.0) Median (range) duration, days 3.5 (1.0–51.0) iiNT,c n (%) Any grade 34 (15) Grade 3/4 7 (3) Grade 5 0 Median (range) time to first onset, daysb 3.0 (1.0–317.0) Medi

  19. Slide 19: Expanding ABECMA manufacturing footprint

    Expanding ABECMA manufacturing footprint Thermo Fisher Current commercial adherent LVV capacity Approximately 70 treatment centers in the U.S. as of 2022 Summit, NJ Drug product facility supporting global commercial launch. Successfully increasing monthly capacity. Resilience sLVV, significant incre

  20. Slide 20: Pipeline

    INDICATION [DRUG] TARGET TECHNOLOGY DISCOVERY STAGE R&D IND-ENABLING PRECLINICAL STUDIES CLINICAL STUDIES APPROVED PRODUCTS Multiple Myeloma [ABECMA] BCMA CAR T cell Multiple Myeloma [ABECMA] BCMA CAR T cell AML-Pediatric [SC-DARIC33] CD33 Drug-Regulated; CAR T cell (DARIC) B-NHL [bbT369] Dual B cel

  21. Slide 21: Long-term partnership track record

    Long-term partnership track record New collaborations are a key focus over next three years 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Initial collaboration with Celgene (BMS) to advance gene therapies in oncology; $75M upfront – 1Q 2013 Updated / narrowed focus on anti-BCMA; $25M – 2Q 2

  22. Slide 22: REGN Collaboration 2.0: Combinatorial Potential of Engineered T cells

    REGN Collaboration 2.0: The Combinatorial Potential of Engineered T cells Leverages 2seventy’s CAR/TCR Platform with Regeneron mAbs and Bi-specifics for Solid Tumors • Builds on several previously identified product candidates advancing toward the clinic including MUC16 • Combines engineered T cells

  23. Slide 23: 2seventy's end-to-end capabilities designed to unleash the cure

    2seventy’s end-to-end capabilities designed to unleash the cure Research Platform with transformative toolkit Manufacturing Horsepower (270-MPH) to increase speed, control costs, and improve learning/iteration Translational Engine to run multiple parallel studies, integrating knowledge across all as

  24. Slide 24: T cell research platform built to rapidly design, test, learn, & iterate

    T cell research platform built to rapidly design, test, learn, & iterate 1 2 3 4 5 VECTOROLOGY Maximize payload, innovative design, optimize component co-expression 4 DESIGN LVV mRNA MODALITY Take T cells to the next level, explore in vivo delivery 5 ab T CELLS in vivo LVV MANUFACTURING Commoditize

  25. Slide 25: New in-house manufacturing facility (270-MPH)

    2seventy bio’s NEW in-house manufacturing facility (270-MPH) The heart of our translational cell therapy engine Enable Fully Integrated Translational Cell Therapy Platform ➢ Enables manufacture and release of drug product for multiple Phase I clinical trials ➢ Co-located @ 60 Binney with research, P

  26. Slide 26: Majority of B-NHL patients ultimately fail CAR T therapy

    Despite transforming the treatment paradigm of B-NHL, the majority of patients ultimately fail CAR T therapy We identified four key challenges in current CAR T therapies 26 CD19 Loss Target-Antigen Downregulation Loss of Tumor cell co- stimulatory ligands Challenges in B-NHL CAR T ~30% of CD19 CAR T

  27. Slide 27: bbT369: Novel CAR T candidate purpose-built for B-NHL

    bbT369: Novel CAR T candidate purpose-built to address needs in B-NHL • Designed to address outstanding need in B-NHL – we believe bbT369 has the potential to increase response rate and durability of response for a larger fraction of patients. • Novel combination of antigens to address antigen escap

  28. Slide 28: bbT369: Complete and durable tumor control in lymphoma mouse models

    bbT369: Complete and durable tumor control in lymphoma mouse models bbT369 -20 20 40 60 80 100 120 0 1000 2000 3000 4000 0 500 1000 1500 2000 2500 Days Tu m or V ol . ( m m 3 ) Avg T Cells /  L CAR T Cell expansion Tumor -20 20 40 60 80 100 120 0 1000 2000 3000 4000 0 500 1000 1500 2000 2500 Days T

  29. Slide 29: CRC-403 study in B-NHL open and enrolling

    CRC-403 study in B-NHL open and enrolling 29 day -5 -2 day 0 day 0-30 day 30 CRC-403: A Phase 1/2 Study of bbT369 in Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) Key Questions / Features QUESTIONS • Is the safety and tolerability of bbT369 in line with prior CAR Ts? • Does bbT369 s

  30. Slide 30: Engineered cell therapies have the potential to overcome key challenges in AML

    Engineered cell therapies have the potential to overcome key challenges in AML 30 Description of issue AML targets are expressed on healthy myeloid lineage & progenitor cells; Aplasia related toxicities are likely to emerge if targeted robustly & constitutively AML originates from myeloid progenitor

  31. Slide 31: SC-DARIC33: CD33 targeted CAR T cell with drug-regulated ON/OFF states

    SC-DARIC33: CD33 targeted CAR T cell with drug-regulated ON/OFF states ➢DARIC: a switchable CAR architecture that potentially addresses fundamental AML challenges… • Architecture enables T cell activity to be turned ON and OFF • ON state occurs at non-immunosuppressive rapamycin dose levels • OFF st

  32. Slide 32: SC-DARIC33 in AML: drug-regulated tumor control in preclinical studies

    SC-DARIC33 in AML: Sensitive, drug-regulated tumor control achieved in preclinical studies SC-DARIC33 TARGET(S) CD33-C2 TECH VHH binder Drug-regulated DARIC architecture TARGET INDICATION R/R AML pediatrics / young adults STATUS Ph1 Trial Enrolling PARTNER • Aggressively targeting AML requires pharm

  33. Slide 33: Phase I study (PLAT-08) open and enrolling

    Phase I study (PLAT-08) open and enrolling 33 Study Design: A Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Key Questions / Features QUESTONS • Do SC-DARIC33 T cells engraft & show activity vs CD33+ve cells? • Is SC-DARIC33 safe and does it drive a clinical

  34. Slide 34: Differentiated toolbox aims to attack solid tumors

    2seventy’s differentiated toolbox aims to attack solid tumors by addressing key barriers to success 34 We seek to achieve sensitive & multiplex targeting across the full range of target classes Tumor/Target Heterogeneity CAR TECH TCR TECH NEXT GEN We seek to disrupt the biological barriers to T cell

  35. Slide 35: MUC16 CAR T displays robust activity in tumor rechallenge mouse model

    MUC16 CAR T displays robust activity in tumor rechallenge mouse model MUC16 / Ovarian cancer program: designed to exploit the power of CAR T + pharmaceutical combination strategies to unlock deep responses Ovarian Cancer MUC16 CAR T Combo TARGET(S) MUC16 TECH CAR targeting prevalent MUC16 membrane-r

  36. Slide 36: Exploring the potential of combinations to unlock solid tumors

    Exploring the potential of combinations to unlock solid tumors Deepened Regeneron collaboration enables potential for clinical testing of MUC16 CAR T + mAbs and/or bi-specifics Anti-CD28 Tumor targeted co-stimulation Robust toolbox with the potential to unlock deep responses in Ovarian Cancer PD-1 i

  37. Slide 37: MAGE-A4 Expressing Solid Tumor Program

    MAGE-A4 Expressing Solid Tumor Program: A powerful MAGE-A4 TCR potency enhanced with a “flip” receptor to neutralize TGFb Solid Tumor MAGE-A4 TCR-T Cell Therapy TARGET(S) MAGE-A4 (HLA-A*02) TECH • MAGE-A4 directed TCR • CTBR12 TGFβ flip receptor TARGET INDICATION Solid tumors STATUS Preclinical PART

  38. Slide 38: MegaTAL Gene Editing for Hemophilia A / FVIII

    MegaTAL Gene Editing for Hemophilia A / FVIII TARGET(S) Endogenous gene promoter trap knock-in of F8 transgene TECH • TSVT megaTAL gene edit • TSVT in vivo grade mRNA production / purification platform • AAV for transgene delivery • Genevant LNPs for hepatocyte delivery TARGET INDICATION Hemophilia

  39. Slide 39: Leadership

    Leadership 2seventy team 39 Board of Directors Philip Gregory, D. Phil. Chief Scientific Officer Chip Baird Chief Financial Officer Nick Leschly Chief Kairos Officer* Dan Lynch Board Chair Jenn Snyder Head of Corporate Affairs + ~410 awesome timekeepers Ramy Ibrahim, M.D. BIT.BIO Marcela Maus, M.D.,

  40. Slide 40: thank you

    thank you

2seventy bio — Investor Presentation (March 2023) on 6ix